Polycomb repressive complex 2 (PRC2) is a major epigenetic repressive complex, the core of which is composed of EED, SUZ12 and a catalytic subunit, either EZH1 or EZH2. PRC2 trimethylates histone H3 on lysine 27 (H3K27me3), an epigenetic mark associated with transcriptional repression. 9 Recently, EZH1 was also found to form a distinct complex containing SUZ12 but not EED that activates genes in association with increased H3K27me1 and H3K4me3. Rationale: Polycomb repressive complex 2 is a major epigenetic repressor that deposits methylation on histone H3 on lysine 27 (H3K27me) and controls differentiation and function of many cells, including cardiac myocytes. EZH1 and EZH2 are 2 alternative catalytic subunits with partial functional redundancy. The relative roles of EZH1 and EZH2 in heart development and regeneration are unknown.
A dult mammalian cardiac myocytes (CMs) have limited capacity to proliferate, and as a result, the adult human heart has little capacity to regenerate from heart injury. 1, 2 Murine heart regeneration potential remains robust into the first postnatal week of life because hearts injured by apical resection or myocardial infarction (MI) on postnatal day 1 (P1) recover with little scar through proliferation of preexisting CMs. 3 This regenerative capacity is lost rapidly because similar injury at P7 induces scar rather than myocardial regeneration. The mechanisms responsible for CM cell cycle exit remain incompletely understood. 4 Reactivation of some transcriptional regulatory networks essential for heart development, such as those controlled by YAP and TBX20, has been shown to promote adult CM cell cycle activity. [4] [5] [6] [7] However, clinically meaningful strategies are still lacking. The barriers likely reside in the intrinsically distinct chromatin states and epigenetic pathways of adult compared with fetal and neonatal CMs, which repress critical regulatory genomic loci required for effective regeneration.
potential and reduced CM cell cycle activity, leading us to hypothesize that Ezh1/2 is required for heart regeneration.
In this work, we studied the relative contribution of Ezh1 versus Ezh2 to heart development and regeneration. We show that Ezh1 and Ezh2 function redundantly to silence ectopic gene transcription in fetal CMs by depositing H3K27me3 in an EZH dose-dependent manner. Surprisingly, Ezh1 but not Ezh2 was required for neonatal heart regeneration. Moreover, overexpression of Ezh1 but not Ezh2 improved myocardial function after MI at postnatal stages with poor innate regenerative capacity. Thus, our results indicate that heart regeneration requires a distinct set of epigenetic regulators from heart development.
Methods
A detailed Materials and Methods used in this study are available in the Online Data Supplement.
Results

Cardiac Ezh1/2 Double Knockout Disrupted Heart Development and Reduced CM Proliferation in an EZH Dose-Dependent Manner
Consistent with previous studies, 12 constitutive Ezh1 knockout (E1KO) mice were phenotypically normal, viable, and fertile and showed no abnormalities in postnatal growth and heart function ( Figure 1A ; Online Figure IA ). To further investigate the effect of PRC2 catalytic subunit EZH1 and EZH2 in early heart development, we inactivated an Ezh2 floxed allele (Ezh2 fl/ fl ) in CMs using cTNTCre (Ezh2 knockout [E2KO]), 13 which is active in differentiated CMs by embryonic day 8.5 (E8.5). 14 Figure IB) . E12.5 and E16.5 DKO embryos were present at the expected Mendelian ratio but exhibited abnormal heart development ( Figure 1A ; Online Figure IC) . Unlike E1KO and E2KO, a majority of DKO mice died perinatally ( Figure 1A ). By E12.5, DKO mutant hearts exhibited hypoplasia of the compact myocardium of both left and right ventricles ( Figure 1B  through 1D ). Both ventricles also had excessive trabeculation.
Hypoplasia of compact myocardium suggested reduced CM proliferation. We stained histological sections of E13.5 DKO and control hearts for phosphorylated histone H3, a cell cycle M-phase marker. Dual inactivation of Ezh1 and Ezh2 caused ≈2.5-fold decrease in phosphorylated histone H3-positive CMs (P<0.05; Online Figure ID and IE). In line with decreased proliferation, the expression of cell cycle inhibitors Ink4a and Ink4b (Mouse Genome informatics: Cdkn2a/b), which we previously showed were repressed by PRC2 in fetal CMs, 13 was dramatically upregulated in E12.5 DKO ventricles (Online Figure IF) , although the extent of upregulation was less in E2KO, coinciding with its normal heart development.
Next, we investigated the molecular regulation of gene expression in DKO hearts. By immunostaining, we found markedly reduced H3K27me3 in E13.5 DKO CMs (Online Figure IG) . Western blotting also showed the global reduction in H3K27me3 in E16.5 DKO heart ( Figure 1E ). Interestingly, H3K27me3 was also significantly reduced in E2KO, but not to the same degree as DKO, whereas it was normal in E1KO. What New Information Does This Article Contribute?
• EZH1 and EZH2 are functionally redundant in differentiated cardiac myocytes for heart development.
• EZH1 but not EZH2 is essential for neonatal heart repair.
• EZH1 promotes heart repair by activating genes involved in cardiac growth.
The adult mammalian heart has limited regenerative capacity after injury. Epigenetic marks such as covalent histone modifications are important regulators of gene expression. However, little is known about the role of the epigenetic regulators in heart development versus regeneration. We investigated the function of EZH1 and EZH2, alternative subunits of polycomb repressive complex 2, a major epigenetic repressor complex, in heart development and regeneration. Our data show that in developing heart, EZH1 and EZH2 function redundantly to silence ectopic gene transcription by depositing repressive histone mark H3K27me3. Surprisingly, EZH1, but not EZH2, was required for heart regeneration after neonatal myocardial infarction. Moreover, overexpression of EZH1 but not EZH2 improved myocardial function after myocardial infarction at postnatal stages with poor innate regenerative capacity. EZH1 activated cardiac growth genes to promote heart repair by enhancing the deposition of active histone marks. These findings suggest that heart regeneration requires epigenetic regulators and mechanisms that differ from those involved in heart development.
These data suggest that Ezh2 is the main catalytic subunit of PRC2 in fetal CMs, but Ezh1 provides partial functional compensation after Ezh2 ablation. This level of compensation is sufficient to support normal heart development. We also found that H3K27me1 and H3K27me2, also deposited by PRC2, were reduced ( Figure 1E ) in DKO. Interestingly, H3K27me2 was not different between E2KO and DKO, suggesting that Ezh1 does not compensate for its global level, and that global H3K27me2 level is not critically linked to normal heart development. We globally measured gene expression by RNA analysis by next-generation sequencing in E1KO, E2KO, and DKO.
A large number of genes (399) were uniquely upregulated in DKO, and 212 genes were shared between DKO and E2KO ( Figure 1F ). Quantitative analysis of gene expression levels showed that the extent of gene dysregulation was much greater in DKO compared with E1KO or E2KO ( Figure 1G ). The promoters (TSS ±5 kb) of the majority of these differentially expressed genes were occupied by H3K27me3 in controls ( Figure 1G ). Further analysis of the direction of differential expression (up-or downregulated) and the presence of H3K27me3 at the promoter indicated that upregulated genes were significantly enriched for H3K27me3 ( Figure 1H ). These results suggest that most genes upregulated in DKO are normally directly repressed by PRC2. Gene ontology term analysis of upregulated genes showed that these upregulated genes are enriched for functional terms related to development, cell proliferation, and noncardiac gene expression programs (Online Figure II) . Together, these results show that EZH1 and EZH2 function redundantly and regulate heart development by depositing H3K27me3 and repressing noncardiac gene programs. Figure 2A ). At 3 weeks after MI, both control (Ezh2 fl/fl ) and E2KO hearts had little fibrotic scar ( Figure 2B and 2C), indicating that Ezh2 is dispensable for neonatal heart regeneration (data not shown). In contrast, E1KO mice had markedly increased fibrotic scar from 1 to 3 weeks after MI ( Figure 2B and 2D). Consistent with impaired myocardial regeneration, E1KO mice had severely depressed heart function, as measured by echocardiography ( Figure 2E ). CM proliferation, measured by EdU incorporation and staining of transverse tissue sections, was clearly reduced in the border zone of E1KO (Online Figure III) . These results indicate that Ezh1 but not Ezh2 is essential for cardiac regeneration after neonatal MI.
EZH1 but Not EZH2 Was Essential for Heart Regeneration
To confirm the differential requirement of Ezh1 and Ezh2 in this context, we performed a rescue experiment in which AAV9-cTNT-Ezh1, -Ezh2, or -GFP (control) were delivered to E1KO mice at P5, when MI was also induced ( Figure 3A ; Online Figure IVA) . We validated overexpression of EZH1, EZH2, and GFP proteins in CMs (Online Figure IVB through  IVD) . CM-specific re-expression of Ezh1, but not Ezh2 or GFP, dramatically reduced fibrosis area of injured E1KO hearts ( Figure 3B and 3C ) and improved heart function ( Figure 3D ). We also examined CM proliferation in the rescue experiment. Ezh1 overexpression increased the incidence of EdU + CMs by nearly 7-fold relative to Ezh2 or GFP overexpression (Online Figure III) . Unlike EZH1, overexpression of EZH2 in E1KO did not rescue fibrosis or heart function ( Figure 3B through 3D). These results confirm the key role of Ezh1 in heart regeneration and show that Ezh2 cannot functionally replace Ezh1 in cardiac regeneration. Furthermore, because AAV9 with Tnnt2 promoter selectively drives gene expression in CMs, these data demonstrate that CMs are the cell type that requires Ezh1 for effective cardiac regeneration. Collectively, these data support the crucial role of EZH1 in neonatal heart regeneration through modulating CM proliferation.
EZH1 Overexpression Prolongs the Heart Regeneration Window
Because Ezh1 played a crucial role in both heart morphogenesis and regeneration, we next tested the hypothesis that Ezh1 might be sufficient to prolong the window during which the neonatal murine heart remains competent for regeneration. By P7, murine hearts have lost regenerative capacity, and as a result, myocardium lost from myocardial infarction is replaced by fibrotic scar. We studied the effect of overexpression of AAV9-expressed Ezh1, Ezh2, or GFP on heart regeneration after MI induced at P10, well outside the innate regenerative window ( Figure 4A ). Histological evaluation 3 weeks after MI showed that AAV-Ezh1 markedly and significantly reduced fibrotic scar area compared with AAV-GFP, whereas AAV-Ezh2 had no significant effect ( Figure 4B and 4C) . Echocardiography demonstrated that AAV-Ezh1 significantly improved heart function compared with AAV-GFP, whereas AAV-Ezh2 was ineffective ( Figure 4D) .
To examine the cellular mechanism, we measured CM proliferation by EdU staining. We found that EdU + CM frequency in the border zone of AAV-Ezh1 hearts was significantly greater than AAV-GFP, and AAV-Ezh2 did not have a significant effect (Online Figure VIA and VIB) . To study the effect of To dissect the molecular mechanism underlying enhanced CM proliferation and survival induced by Ezh1 overexpression, we profiled gene expression by RNA analysis by nextgeneration sequencing and genomic occupancy of EZH1, H3K27me3, H3K27ac, and H3K4me3 by chromatin immunoprecipitation followed by next-generation sequencing. Compared with AAV-GFP mice, 597 and 182 differentially expressed genes were significantly up-and downregulated, respectively, in AAV-Ezh1 heart after MI (Online Figure  VIIA) . Upregulated genes were enriched in GO terms related to embryonic morphogenesis and cardiac muscle growth ( Figure 4E ), whereas downregulated genes did not yield any significantly enriched terms. Quantitative RT-PCR validated 7 of 11 upregulated genes involved in fetal heart development (Online Figure VIIB) . EZH1 deposits H3K27me3, canonically a repressive histone mark. 9 A distinct EZH1-containing protein complex has been shown to activate genes in association with accumulation of H3K4me3 and H3K27me1, 10, 11 histone marks which have been linked to gene activation. 16 To examine the mechanism of gene dysregulation, we measured H3K27me1/2/3 bulk levels by immunoblotting. Surprisingly, compared with AAV-GFP treatment, AAV-Ezh1 caused a reduction in overall H3K27me3 and a clear increase in H3K27me1 ( Figure 4F ). This result was further reinforced by genome-wide profiling of EZH1, H3K27me3, and H3K27ac chromatin occupancy by chromatin immunoprecipitation followed by next-generation sequencing. This showed that overexpressed EZH1 was found at the TSS of most upregulated genes ( Figure 4G ). Consistent with bulk levels, H3K27me3 occupancy of many upregulated genes was reduced by AAV-Ezh1 ( Figure 4G ). Furthermore, only 5535 of 31 124 (17.8%) EZH1 peaks overlapped with H3K27me3 peaks (Online Figure VIIC) . These data suggest that EZH1 has alternate mechanism that is not dependent on deposition of H3K27me3. In agreement with the reported activation role of EZH1, 10, 11 we observed substantial overlap between EZH1 and H3K4me3 occupied chromatin regions (Online Figure VIID) , including at promoters (±5 kb of TSS) of upregulated genes ( Figure 4G ). However, H3K27ac, a marker of active enhancers and promoters, did not obviously change at these promoters ( Figure 4G ). Together, these data suggest that EZH1 upregulates genes by increasing H3K27me1 levels and activating heart growth-related genes, leading to augmented proliferation and survival during heart regeneration after injury.
Discussion
Recent studies highlight strategies that redeploy developmental signaling pathways to achieve the goals of cardiac regeneration 4 and point to epigenetic barriers to effective regeneration in mammalian hearts 17 Previous work by us and others suggested that Ezh1 is functionally redundant with Ezh2 in differentiated CMs. 13, 18, 19 Here, we provide direct evidence that Ezh1 and Ezh2 complement each other in heart development. Furthermore, we extended the analysis of Ezh1 and Ezh2 function to heart regeneration and made the surprising discovery that these genes have distinct activities in regeneration compared with development. Specifically, whereas Ezh2 was functionally dominant in development but dispensable for regeneration, Ezh1 contributed to heart development and was essential for heart regeneration. Indeed, Ezh1 was sufficient to enhance regeneration in 10-day-old hearts, which normally lack regenerative capacity. It will be important to evaluate the ability of Ezh1 overexpression to improve myocardial outcome after adult heart injury. The molecular mechanisms underlying EZH1/2 activity in development and regeneration were also distinct. As shown in He et al 13 and this study, during development, Ezh2 and, to a lesser (but functionally sufficient) degree Ezh1, deposited H3K27me3 and repressed noncardiac gene programs. In regeneration, likely through globally increasing H3K27me1, EZH1 directly targeted and upregulated genes, related to cardiac growth and marked by H3K4me3. This suggests that EZH1 functions in regeneration in an EZH1-SUZ12 complex lacking EED that has been linked to transcriptional activation and associated with H3K4me3 and H3K27me1. 10 Further experiments will be required to further define the EZH1-containing protein complex required for heart regeneration.
Collectively, our work illuminates a novel role for EZH1 in heart regeneration and illustrates the divergent role of epigenetic regulators in heart development and regeneration, as summarized in the working model (Online Figure VIII) . Further interrogation of the factors that enhance or decrease competence for neonatal cardiac regeneration may provide a framework for resetting the epigenetic landscape to enhance myocardial outcome after heart injury.
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